spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  VTE  

 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2021
FDA Approves Verzenio(R) (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Oct 2019
FDA Clears GEKO DEVICE for Use in Non-surgical Patients at Risk for Deep Vein Thrombosis Based on Study Demonstrating a Zero Percent DVT Rate in Patients After a Stroke
Devices FDA
 HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Aug 2018
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA(R) (edoxaban)
Biopharmaceuticals
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2018
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2015
Boston Scientific Receives FDA Approval And CE Mark For AngioJet(TM) ZelanteDVT(TM) Thrombectomy Catheter
Devices Interventional FDA Regulatory
 HSMN NewsFeed - 7 Aug 2015
NICE Recommends Once-daily Lixiana(R) (Edoxaban) for Preventing Stroke and Systemic Embolism in People with Non-valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 15 Jul 2014
Pradaxa(R) (dabigatran etexilate) Now Available in the UK for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrence
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Mar 2014
AngioDynamics Receives Expanded FDA Clearance for AngioVac
Devices Cardiology FDA
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Jul 2013
Instrumentation Laboratory Launches HemosIL(R) FDP Assay In Europe, Asia And Other International Regions
Diagnostics Product Launch
 HSMN NewsFeed - 10 Apr 2013
Kaleidoscope Medical Secures Series A Funding
Devices Venture Capital
 HSMN NewsFeed - 25 Jun 2012
Bristol-Myers Squibb and Pfizer Receive Complete Response Letter from U.S. Food and Drug Administration for ELIQUIS(R) (apixaban)
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2011
ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Biopharmaceuticals Surgery Orthopaedic
 HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 31 Aug 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2010
Instrumentation Laboratory Receives 510(K) Clearance From FDA and Canadian License for HemosIL(R) D-Dimer HS 500 Assay
Diagnostics FDA Regulatory
 HSMN NewsFeed - 17 Aug 2009
Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
Biopharmaceuticals
 HSMN NewsFeed - 24 Sep 2008
Nice Approves Pradaxa(R)*(Dabigatran Etexilate) - First New Oral Anticoagulant in the UK for Over 50 Years
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2008
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
Diagnostics FDA
 HSMN NewsFeed - 30 Jul 2008
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jul 2008
Chest Physicians Now Suggest Early Intervention for Certain Blood Clots in DVT
Devices Interventional
 HSMN NewsFeed - 30 May 2008
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 27 Mar 2008
Novel Oral Anticoagulant Pradaxa(R) (dabigatran etexilate) Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Feb 2008
GTx's Toremifene Citrate 80 mg Meets Primary and Key Endpoints in Phase III Trial in Advanced Prostate Cancer Patients on Androgen Deprivation Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2008
Clexane(R)/Lovenox(R) Approved in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
 HSMN NewsFeed - 11 Jul 2007
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2007
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2007
New Study Shows That Extending Prophylaxis With Clexane(R) / Lovenox(R) (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Biopharmaceuticals
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Apr 2007
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2007
The Lancet Publishes PREVAIL Study Results Showing Lovenox(R) Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 25 Mar 2007
Data Shows That Omission of Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Medical Patients Is Frequent and Leads to Higher Risk of Deep-Vein Thrombosis (DVT)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 1 Feb 2007
Sanofi-aventis Applauds New National Standards for Prophylaxis of Venous Thromboembolism in Surgical Patients
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Clexane(R) / Lovenox(R) (Enoxaparin Sodium Injection) is More Effective Than Unfractionated Heparin (UFH) for Preventing the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2006
New Study Shows Lovenox(R) (Enoxaparin Sodium Injection) Is More Effective Than Unfractionated Heparin (UFH) for Lowering the Risk of Venous Thromboembolism (VTE) in Patients With Acute Ischemic Stroke
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
Positive Phase 3 Results for New Fixed Oral Dose Anticoagulant Presented at 48th Annual Meeting of the American Society of Hematology
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA
Return to NewsFeed  

 Additional items found! 21

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 21 additional stories matching:
VTE
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!